Fuyuan Pharmaceutical: Obtained the approval notification for the application for the marketing of Alamodine active pharmaceutical ingredients.

Fukimoto Pharmaceuticals announced that it has recently received the approval notice for the marketing application of the chemical raw material drug Elalmod issued by the National Medical Products Administration. The notice number is 2026YS00169, and the validity period is until February 27, 2031. This raw material drug is used for the treatment of active rheumatoid arthritis. The technical review application submitted by the company in September 2024 was accepted. This approval will enrich the company's product line and promote its development, but the sales of the drug may be affected by factors such as policies and market environment, leading to uncertainties.